Mark O’Carroll

Clonal strains of<i>Pseudomonas aeruginosa</i>in paediatric and adult cystic fibrosis units

Mark O’Carroll, Melanie W. Syrmis, Claire Wainwright et al. · European Respiratory Journal · 2004 · 114 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +17

Vanzacaftor–tezacaftor–deutivacaftor versus elexacaftor–tezacaftor–ivacaftor in individuals with cystic fibrosis aged 12 years and older (SKYLINE Trials VX20-121-102 and VX20-121-103): results from two randomised, active-controlled, phase 3 trials

Claire Keating, Lael M. Yonker, F. Vermeulen et al. · The Lancet Respiratory Medicine · 2025 · 89 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Burkholderia pseudomallei: another emerging pathogen in cystic fibrosis

Mark O’Carroll · Thorax · 2003 · 69 citations · Full text

Medicine, Infectious Diseases, Microbiology +9

Diagnostic yield of bronchoscopic sampling in febrile neutropenic patients with pulmonary infiltrate and haematological disorders

Aruni Seneviratna, Mark O’Carroll, Cornelius Lewis et al. · Internal Medicine Journal · 2011 · 29 citations

Medicine, Clinical Sciences, Hematology +13

Polymyxin B and ethylenediaminetetraacetic acid act synergistically against <i>Pseudomonas aeruginosa</i> and <i>Staphylococcus aureus</i>

Samuel J. M. Hale, Alan J. Cameron, Christian A. Lux et al. · Microbiology Spectrum · 2024 · 11 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +16